Takeda Pharmaceutical Co. Ltd.'s $62bn planned acquisition of Shire PLC may be moving ahead - pending shareholder approval - but in many ways the hard work is just beginning, even after a protracted pursuit that saw the Japanese firm raise its bid five times before final success.
While the acquisition of a late-stage pipeline and products in new niche areas are being seen as the main benefits...







